Actively Recruiting

Phase Not Applicable
Age: 5Years +
All Genders
NCT03344016

Multicenter Pheochromocytoma and Paraganglioma Evaluation

Led by Felix Beuschlein · Updated on 2020-07-09

1148

Participants Needed

1

Research Sites

1200 weeks

Total Duration

On this page

Sponsors

F

Felix Beuschlein

Lead Sponsor

T

Technische Universität Dresden

Collaborating Sponsor

AI-Summary

What this Trial Is About

Target population: Patients with (1) newly diagnosed or (2) past history of pheochromocytomas and paragangliomas (PPGL) or (3) carrier of genetic mutations in known PPGL susceptibility genes. International multicenter prospective cohort study with randomized intervention (special care follow-up vs. standard care follow-up). All patients will receive instructions about follow-up at the time point of study inclusion. Patients randomized to the standard care follow-up group will be advised to return annually for follow-up according to current routine practice (without active re-scheduling). In contrast, patients randomized to the special care follow-up group will also be advised to return annually for follow-up but these patients will be actively invited, re-scheduled and reminded by the centers to meet scheduled follow-up appointments.

CONDITIONS

Official Title

Multicenter Pheochromocytoma and Paraganglioma Evaluation

Who Can Participate

Age: 5Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male and female patients aged 5 years or older
  • Patients with a newly diagnosed pheochromocytoma or paraganglioma (PPGL)
  • Patients with a previous history of PPGLs
  • Carriers of genetic mutations known to increase risk for PPGLs
  • Ability to read, understand, and sign informed consent (parental consent for children)
Not Eligible

You will not qualify if you...

  • Patients unable to provide informed consent due to impaired mental capacity
  • Pregnant women will not undergo Clonidine testing, PET, MIBG scanning, or contrast CT
  • Patients with implantable metal or anxiety that prevents MRI cannot undergo MRI scanning

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University Hospital Zurich

Zurich, Switzerland, 8091

Actively Recruiting

Loading map...

Research Team

F

Felix Beuschlein, M.D.

CONTACT

M

Martin Reincke, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

HEALTH_SERVICES_RESEARCH

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here